Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 13: ONTARGET - objectives Abb. 14: ONTARGET - a global trial Abb. 15: ONTARGET - participating countries Aktuelles Bild - Abb. 16: ONTARGET will be the largest ARB trial to date Abb. 17: ONTARGET - patient profile Abb. 18: ONTARGET - study design Abb. 19: ONTARGET - study design Zum letzten Bild
Abbildung 16: ONTARGET will be the largest ARB trial to date
There are many ongoing clinical trials involving ARBs. However, with an anticipated patient recruitment target of 23,400 and an expected duration of up to 5.5 years, ONTARGET is the largest ARB trial ever undertaken. The ongoing Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study compares telmisartan with the ACE inhibitor, enalapril, in patients with hypertension and concurrent type II diabetes and diabetic nephropathy. Patients (n=272) will be followed up for 5 years. [10] The Irbesartan type II Diabetic Nephropathy Trial (IDNT) was a 3-year trial studying the effect of irbesartan on the progression of renal disease and mortality in 1715 type II diabetic patients with overt nephropathy and hypertension. [11] Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity (CHARM) is an ongoing programme investigating the clinical usefulness of candesartan cilexetil. Approximately 7600 patients have been enrolled and will be followed up for a minimum of 2 years.8 The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial compares the ARB, valsartan, with the calcium channel blocker, amlodipine. The incidence of cardiac morbidity and mortality will be studied in 15,320 patients for approximately 4 years. [12] The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study is an ongoing trial comparing the effects of losartan with those of the beta-blocker, atenolol, on the reduction of cardiovascular morbidity and mortality in 9194 patients. It is expected to continue for at least 4 years (until 1450 patients reach a primary endpoint). [13, 14] 8. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-282. 10. Rippin J, Bain SC, Barnett AH. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2001;In press. 11. Rodby RA, Rohde RD, Clarke WR, et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000;15:487-497. 12. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-183. 13. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. Am J Hypertens 1997;10;705-713. 14. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension 1998;32:989-997.
 
ONTARGET will be the largest ARB trial to date
Vorheriges Bild Nächstes Bild   


Abbildung 16: ONTARGET will be the largest ARB trial to date
There are many ongoing clinical trials involving ARBs. However, with an anticipated patient recruitment target of 23,400 and an expected duration of up to 5.5 years, ONTARGET is the largest ARB trial ever undertaken. The ongoing Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study compares telmisartan with the ACE inhibitor, enalapril, in patients with hypertension and concurrent type II diabetes and diabetic nephropathy. Patients (n=272) will be followed up for 5 years. [10] The Irbesartan type II Diabetic Nephropathy Trial (IDNT) was a 3-year trial studying the effect of irbesartan on the progression of renal disease and mortality in 1715 type II diabetic patients with overt nephropathy and hypertension. [11] Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity (CHARM) is an ongoing programme investigating the clinical usefulness of candesartan cilexetil. Approximately 7600 patients have been enrolled and will be followed up for a minimum of 2 years.8 The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial compares the ARB, valsartan, with the calcium channel blocker, amlodipine. The incidence of cardiac morbidity and mortality will be studied in 15,320 patients for approximately 4 years. [12] The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study is an ongoing trial comparing the effects of losartan with those of the beta-blocker, atenolol, on the reduction of cardiovascular morbidity and mortality in 9194 patients. It is expected to continue for at least 4 years (until 1450 patients reach a primary endpoint). [13, 14] 8. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-282. 10. Rippin J, Bain SC, Barnett AH. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2001;In press. 11. Rodby RA, Rohde RD, Clarke WR, et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000;15:487-497. 12. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-183. 13. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. Am J Hypertens 1997;10;705-713. 14. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension 1998;32:989-997.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung